Intellia identifies genetic risk factor for liver complications in CRISPR trial
Intellia Therapeutics said it discovered a common link among the patients who faced the highest liver enzyme elevations after receiving its CRISPR gene editing treatment for ATTR amyloidosis. The gene editing ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.